Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023426 · ClinicalTrials.gov registry record · Phase 2
TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis
A Phase 2 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00023426 is a Phase 2 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 150 participants.
The verdict
NCT00023426, a Phase 2 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
Randomized, double-blind study of the tolerability of three different doses of rifapentine
Interventions
- DRUG rifapentine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 1999-07 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023426
The ClinicalTrials.gov registry entry for NCT00023426 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rifapentine is the first listed.
NCT00023426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023426 about?
NCT00023426 is a clinical study titled "TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis". Randomized, double-blind study of the tolerability of three different doses of rifapentine
What is the current status of trial NCT00023426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 1999-07. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00023426?
The interventions under investigation include: rifapentine (DRUG).
Who is sponsoring clinical trial NCT00023426?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.